Argenx.com

argenx Homepage

WEBReaching Patients Through. Immunology Innovation. The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels …

Actived: 3 days ago

URL: https://www.argenx.com/

Patient Support Program VYVGART (efgartigimod alfa-fcab)

WEBThe committed team of Case Coordinators and Nurse Case Managers at My VYVGART Path offers:. Patient-specific benefit verifications, including confirming out-of-pocket …

Category: Health Go Health

Immune Thrombocytopenia (ITP) Argenx

WEBITP is a rare, often chronic bleeding disorder where reduced numbers of platelets (cells that stop or prevent bleeding) can lead to an increased risk of bleeding and bruising, and an …

Category: Health Go Health

argenx Reports Topline Results from ADVANCE-SC Study of …

WEBAbout the ADVANCE-SC Study. The ADVANCE-SC trial was a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating the efficacy and …

Category: Health Go Health

argenx Highlights Strategic Priorities for 2022 Argenx

WEBargenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its …

Category: Health Go Health

Healthcare Reform

WEBHealthcare Reform In the U.S., the EU and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare systems that could affect …

Category: Health Go Health

argenx Announces U.S. Food and Drug Administration (FDA) …

WEBargenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis VYVGART is the first-and …

Category: Food Go Health

argenx Highlights 2024 Strategic Priorities Argenx

WEBJanuary 8, 2024. argenx Highlights 2024 Strategic Priorities. Amsterdam, the Netherlands. Reported $1.2 billion in preliminary* full-year 2023 global net product sales. Submitted …

Category: Health Go Health

Healthcare Law and Regulation

WEBOn May 21, 2021, PhRMA sued the HHS in the U.S. District Court for the District of Columbia, to stop the implementation of the rule claiming that the rule contradicts federal …

Category: Health Go Health

2019 R&D Day May 22, 2019

WEB8:30 AM: argenx Today: Building Leadership in Immunology Tim Van Hauwermeiren, CEO 8:45 AM: ARGX-117: Renaissance in Complement - Therapeutic Potential of C2 Karen …

Category: Health Go Health

argenx Innovation

WEBThe Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and …

Category: Health Go Health

2022 Environmental, Social and Governance Report

WEB2 2022 E Report Table of Contents Message from our CEO 03 The argenx Purpose 04 Our Philosophy on ESG 06 Patients 07 People 21 Governance 29 Planet 35

Category: Health Go Health

argenx Reports Positive Topline Data from ADHERE Study of …

WEBargenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today …

Category: Health Go Health

argenx Announces Positive Phase 3 Data from ADVANCE Trial of …

WEBargenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today …

Category: Health Go Health

argenx to Present at 42nd Annual J.P. Morgan Healthcare …

WEBargenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that …

Category: Health Go Health

HIGHLIGHTS OF PRESCRIBING INFORMATION

WEBinstitute appropriate measures if needed or the patient should seek medical attention. VYVGART is contraindicated in patients with a history of serious hypersensitivity to …

Category: Medical Go Health

argenx Announces European Commission Approval of …

WEBargenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, …

Category: Health Go Health

argenx Announces Positive Topline Phase 3 Data from ADAPT …

WEBThe Phase 3 ADAPT-SC trial was a randomized, open-label, parallel-group, multicenter trial evaluating the noninferiority of the pharmacodynamic (PD) effect of SC efgartigimod …

Category: Health Go Health

argenx and Zai Lab Announce Strategic Collaboration for …

WEBZai Lab will recruit Chinese patients to argenx’s global registrational trials for the development of efgartigimod. Additionally, this agreement is expected to allow argenx to …

Category: Health Go Health

Long-Term Safety, Tolerability, and Efficacy of Efgartigimod in

WEBPatients needed to have an MG-ADL score ≥5 (>50% from nonocular items) and needed to have a reduction in MG-ADL total score <2 points from study/cycle baseline to be …

Category: Health Go Health

Top Categories

› Appendicitis

› Gout

› Women's Health

› Thyroid

› Sleep

› Skin

› Sexual Health

› Senior Health

› Oral Health

› Mental Health

› Men's Health

› Medications

› Lung Conditions

› Infectious Disease

Popular Searched

› Healthtrust nh globalscape eft

› Health plan phone number

› Va fargo mental health

› Greg wood scottish health

› Sutter health e visit questionnaire

› Find doctor health first

› National healthy start epic center

› Add health couples contract

› Health by design canada

› Eat healthy be active activities

Recently Searched

› Uni key health gla 90

› Visual health doctors of optometry

› Best health insurance for australia

› Sag aftra sydney health

› Dpv health epping centre

› Atrium health cancel appointment

› Myhealthevet support phone number

› Pokemon go health articles

› United healthcare preferred drug list 2022

› Guidance for behavioral health

The medical information found on the MedRXweb website is designed to support, not to replace the relationship between patient and physician and the medical advice they may provide.